Vertex Planning Partners LLC Has $780,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Vertex Planning Partners LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 3.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,390 shares of the company’s stock after purchasing an additional 179 shares during the quarter. Vertex Planning Partners LLC’s holdings in Johnson & Johnson were worth $780,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Principal Financial Group Inc. boosted its holdings in Johnson & Johnson by 10.5% during the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock worth $562,723,000 after purchasing an additional 329,473 shares during the last quarter. United Bank grew its stake in shares of Johnson & Johnson by 5.6% during the 3rd quarter. United Bank now owns 3,788 shares of the company’s stock worth $614,000 after acquiring an additional 202 shares during the period. Algert Global LLC purchased a new stake in shares of Johnson & Johnson during the 3rd quarter valued at approximately $721,000. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in Johnson & Johnson by 51.0% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 296,000 shares of the company’s stock worth $47,970,000 after buying an additional 100,000 shares during the period. Finally, CreativeOne Wealth LLC lifted its position in shares of Johnson & Johnson by 37.7% during the third quarter. CreativeOne Wealth LLC now owns 16,700 shares of the company’s stock worth $2,706,000 after acquiring an additional 4,575 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $163.22 on Friday. The business’s fifty day moving average is $158.35 and its 200 day moving average is $156.23. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a market cap of $393.33 billion, a price-to-earnings ratio of 24.54, a PEG ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the business earned $2.29 EPS. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Analysts Set New Price Targets

A number of research firms have weighed in on JNJ. Barclays lifted their target price on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Raymond James reduced their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Citigroup dropped their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 10th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.